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Abstract
Introduction: We and others have previously shown that antibodies against cyclic citrullinated proteins (anti-CCP)
precede the development of rheumatoid arthritis (RA) and in a more recent study we reported that individuals
who subsequently developed RA had increased concentrations of several cytokines and chemokines years before
the onset of symptoms of joint disease. Here we aimed to evaluate the prevalence and predictive values of anti-
CCP antibodies of IgG, IgM and IgA isotype in individuals who subsequently developed RA and also to relate these
to cytokines and chemokines, smoking, genetic factors and radiographic score.
Methods: A case-control study (1:4 ratio) was nested within the Medical Biobank and the Maternity cohorts of
Northern Sweden. Patients with RA were identified from blood donors predating the onset of disease by years.
Matched controls were selected randomly from the same registers. IgG, IgA and IgM anti-CCP2 antibodies were
determined using EliA anti-CCP assay on ImmunoCAP 250 (Phadia AB, Uppsala, Sweden).
Results: Of 86 patients with RA identified as blood donors prior to the onset of symptoms, samples were available
from 71 for analyses. The median (Q1 to Q3) predating time was 2.5 years (1.1 to 5.9 years). The sensitivity of anti-
CCP antibodies in the pre-patient samples was 35.2% for IgG, 23.9% for IgA, and 11.8% for IgM. The presence of
IgG and IgA anti-CCP antibodies was highly significant compared with controls. IgG and IgA anti-CCP2 predicted
RA significantly in conditional logistic regression models odds ratio (OR) = 94.1, 95% confidence interval (CI) 12.7 to
695.4 and OR = 11.1, 95% CI 4.4 to 28.1, respectively, the IgM anti-CCP showed borderline significance OR = 2.5
95% CI 0.9 to 6.3. Concentrations of all anti-CCP isotypes increased the closer to the onset of symptoms the
samples were collected with an earlier and higher increase for IgG and IgA compared with IgM anti-CCP. IgA and
IgG anti-CCP positive individuals had different patterns of up-regulated chemokines and also, smoking brought
forward the appearance of IgA anti-CCP antibodies in pre-RA individuals.
Conclusions: Anti-CCP2 antibodies of both the IgG and IgA isotypes pre-dated the onset of RA by years; also, both
IgG and IgA anti-CCP2 antibodies predicted the development of RA, with the highest predictive value for IgG anti-
CCP2 antibodies.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by joint inflammation involving the
synovial tissue and ultimately leading to destruction of
cartilage and bone. The pathogenic processes that lead
to the development of the disease are not fully under-
stood at this point.
We and others have shown that antibodies against citrul-
linated proteins/peptides (ACPA), analysed as anti-cyclic
citrullinated proteins (CCP2) antibodies, precede the devel-
opment of RA by several years [1,2] and that individuals
who had the combination of anti-CCP antibodies together
with either the human leukocyte antigen-shared epitope
(HLA-SE) alleles or with the protein tyrosine phosphatase
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relative risk of developing RA [3,4].
In a more recent study we also reported that indivi-
duals who subsequently developed RA had significantly
increased levels of several cytokines and chemokines
years before the onset of RA [5]. The pattern of the up-
regulated cytokines, related factors and chemokines
represented the adaptive immune system (that is, Th1,
Th2 and Treg cell-related factors), while after disease
onset the involvement and activation of the immune
system appeared to be more general and wide-spread.
Currently little is known about the presence and prog-
nostic significance of different isotypes of anti-CCP anti-
bodies in RA. Studies have shown that anti-CCP2
antibodies of the IgG isotype are associated with radio-
graphic progression in RA [6,7]. Investigators have
shown that IgM anti-CCP2 antibodies are present in
both early and established disease [8] and one later
s t u d ys h o w e dt h a tI g Aa n dI g Ma n t i - C C P 2a n t i b o d i e s
were present in RA and were similarly specific for RA as
IgG anti-CCP2 antibodies [9]. Patients with recent onset
RA and positive for IgA anti-CCP2 antibodies were
reported to suffer a more severe disease course over the
first three years compared with patients negative for IgA
anti-CCP2 antibodies [10] and the number of different
isotypes has recently been related to the long-term
radiographic progression in anti-CCP2 antibody positive
RA patients [11].
In this study we aimed first to investigate the presence
and predictive value of IgG, IgA and IgM isotypes of
anti-CCP2 antibodies in individuals who subsequently
developed RA and to assess their relation to rheumatoid
factors (RFs) cytokines and chemokines, genetic factors,
and smoking habits. Second, we evaluated the predictive
effect of these predating antibodies for radiological pro-
gression after disease onset.
Materials and methods
Pre-patients and controls subjects
A nested case-control study designed with a 1:4 ratio
was performed within the Medical Biobank of Northern
Sweden and Northern Sweden maternity cohort. All
individuals in the county of Västerbotten are continu-
ously invited to donate to the Medical Biobank, the
study cohort is population based and no one is
excluded. All pregnant women screened for rubella con-
stitute the maternity cohort. The conditions for recruit-
ment and collection and storage of blood samples have
been described previously [1] The register of patients
with early RA attending the Department of Rheumatol-
ogy at the University Hospital in Umeå and fulfilling the
American College of Rheumatology classification criteria
[12] for RA was co-analysed with those of the cohorts.
The co-analyses identified 86 individuals (65 women
and 21 men) who had donated blood samples before the
onset of any symptoms of RA. Samples were available
for analysis in this study from 71 of the 86 individuals
identified. The median (interquartile range) period of
time predating the onset of symptoms was 2.5 years (1.1
to 5.9 years). For every pre-patient, four control subjects
were randomly selected from the same cohorts and
matched for sex, age at the time of blood sampling, and
area of residence. A total of 276 control subjects of 284
were available for analysis. Blood samples, collected at
diagnosis of the disease, from 60 of the pre-patients
were also available for analysis. The mean age of the
patients at diagnosis was 54.3 years (range 27.9 to 68.3
years). Data on smoking history were collected and the
donors were classified either as non-smokers or ever
smokers (that is, either current and/or previous smo-
kers). The mean time ± SD to diagnosis after the onset
of symptoms was 7.0 ± 2.9 months. Anterior-posterior
radiographs of the hands, wrists and feet obtained at
baseline and after two years were graded according to
the Larsen score [13].
This study was approved by the Regional Ethics Com-
mittee at the University Hospital, Umeå, Sweden, and all
participants gave their written informed consent.
Analyses of autoantibodies
IgG, IgA and IgM anti-CCP2 antibodies
IgG anti-CCP was determined using EliA anti-CCP assay
on ImmunoCAP 250 (Phadia Diagnostic AB, Uppsala,
Sweden), according to the manufacturer’s instruction.
All samples above the upper limit were diluted further
in order to obtain precise values. This equipment uses
wells coated with the CCP2 antigen, which has exactly
the same composition as in other anti-CCP2 assays, that
is, the Euro-Diagnostica ELISA assay (Arnhem, The
Netherlands) used in our earlier report [1]. Most anti-
CCP2 assays focus on quantitative measurements of
autoantibody levels in the high (positive) range, when
run according to the manufacturer’si n s t r u c t i o n s ,a n d
do not always deliver quantitative results below the
company-defined cut-off. The used equipment was ori-
ginally developed for the measurement of specific IgE
antibodies, that is, very low quantitative levels in the pg
range. It also has a routine application for the measure-
ments of conventional anti-CCP2 of the IgG isotype and
also delivers quantitative values in the low range.
IgA anti-CCP was detected using the EliA IgA method
on the ImmunoCAP 250. The method used the standard
anti-CCP antigen solid phase from the same supplier as
for the IgG anti-CCP measurements with an adaptation
in the standard software. The method is used to detect
specific human IgA antibodiesa g a i n s tv a r i o u sa n t i g e n s ,
by using an anti-human IgA detection antibody. All
samples were diluted 1:100 prior to assay with samples
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the manufacturer’s instruction. The EliA IgA method is
calibrated against WHO Ig reference preparation. Sam-
ple results were transformed from μg/l to U/ml accord-
ing to assay lot specific correction factors. At the time
of use no recommended cut off values were cited by the
manufacturer.
IgM anti-CCP2 antibodies were analysed in the same
way as IgA anti-CCP with a dilution of 1:100.
All analyses on the ImmunoCAP equipment were per-
formed in Uppsala on aliquoted samples which had
been stored at -70°C. In all preceding and actual proce-
dures, patient and control samples were treated equally.
Within-study reference ranges were defined by receiver
operating characteristic (ROC) curves based on the stu-
died population. Repeated analysis of individual samples
during the study period showed stable values.
The anti-CCP antibody analyses used the same anti-
gen as used in our earlier investigation of anti-CCP2
antibodies of the IgG isotype, and the IgG anti-CCP
antibody analyses is consequently a reiteration of our
earlier published anti-CCP2 data [1]. Rheumatoid factors
of the IgA, IgG and IgM isotypes were determined using
ELISAs, as previously described [1].
Analysis of cytokines, cytokine receptors, and chemokines
The concentrations of 29 cytokines, cytokine related fac-
tors and chemokines were measured in plasma samples
from 52 of the pre-patients, using multiplex detection
kits from Bio-Rad (Hercules, CA, USA) as previously
described [5]. The factors analysed were; Interleukin (IL)-
1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12,
IL-13, IL-15, IL-17, Eotaxin, IL-1 receptor antagonist
(Ra), IL-2 receptor(R)alpha, basic fibroblast growth factor
(FGF-basic), granulocyte colony stimulating factor
(G-CSF), granulocyte-macrophage colony stimulating
factor (GM-CSF), interferon (IFN)-g, interferon-inducible
protein (IP-10)/(CXCL10), monocyte chemo-attractant
protein (MCP)-1/(CCL2), macrophage inflammatory pro-
tein (MIP)-1a/(CCL3), MIP-1b/(CCL4), platelet-derived
growth factor-BB (PDGF-BB), tumor necrosis factor
(TNF)-a, vascular endothelial growth factor (VEGF),
monokine induced by interferon-g (MIG/CXCL9), and
macrophage-migration inhibitory factor (MIF).
Analysis of genetic factors
HLA-DRB1 genotyping for 0404 and 0401 was performed
using polymerase chain reaction (PCR) sequence-specific
primers from an HLA-DR low-resolution kit and a HLA-
DRB1*04 sub-typing kit as previously described [3]. The
PTPN22 1858C/T polymorphism (rs2476601) was deter-
mined using an ABI PRISM 7900HT Sequence Detector
System (Applied Biosystems, Foster City, CA, USA) as
previously described [4].
Statistical analysis
Statistical calculations were performed using SPSS for
Windows version 17.0 (SPSS; Chicago, IL, USA). Continu-
ous data were compared by non-parametric analyses with
Wilcoxon’s signed rank test for matched pairs (pre-
patients versus RA patients) and conditional logistic
regression analyses (pre-patients versus matched controls).
Relationships between categorical data (positive versus
negative) were compared using Chi-square analyses or
Fisher’s exact test, when appropriate. Continuous data
within the patient group were assessed using the Stu-
dent’s t-test for independent samples when appropriate.
Variations over time of continuous data within and
between groups were assessed with the Kruskal-Wallis
test or with paired samples t-test (pre-patients versus
RA patients). P-value < 0.05 was considered statistically
significant. No correction for the number of compari-
sons was made unless explicitly stated so. Receiver oper-
ating characteristic (ROC) curves were constructed for
the three anti-CCP2 antibody isotypes to identify cut-
offs according to the value resulting in the combination
of the highest sensitivity and specificity based on sam-
ples from the patients together with the controls. The
cut-off for IgG anti-CCP was 15 U/ml, for IgA anti-CCP
2.5 U/ml and for IgM anti-CCP 90 U/ml.
Results
Characteristics of the individuals with samples before
disease onset (pre-patients) and population based
matched controls are presented in Table 1.
Samples from the 71 individuals before they presented
with any symptoms of joint disease and 276 matched con-
trols analysed for the presence of anti-CCP2 antibodies of
the IgG, IgA and IgM isotypes showed significantly
increased levels, and the concentrations were further
increased when these individuals were diagnosed with RA
(Table 2). The sensitivity for the different isotypes was in
Table 1 Characteristics of the pre-patients (individuals
before the onset of any symptoms of joint disease) and
matched controls
Pre-patients Controls
Number (% female) 71 (80.3) 276 (80.1)
Age (range), years 48.6 (19.6 to 66.9) 50.0 (18.6 to 69.1)
Smoking ever, n (%) 49 (69.0)*** 122/271 (45.0)
HLA-SE alleles, n (%) 38/68 (55.9)** 39/116 (33.6)
PTPN22 1858T, n (%) 28 (39.4)** 47/210 (22.4)
Anti-CCP2 antibodies
E (%) 23 (32.4)*** 4 (1.5)
IgM RF, n (%) 17 (22.4)*** 14 (5.1)
IgA RF, n (%) 28 (36.8)*** 12 (4.3)
IgG RF, n (%) 15 (19.7)*** 14 (5.1)
**P < 0.01, ***P < 0.001,
E analysed with a kit from Euro-Diagnostica. HLA-SE,
human-leukocyte antigen - shared epitope; PTPN22, protein tyrosine
phosphatase non-receptor type 22; Anti-CCP, anti-cyclic citrullinated peptide;
Ig, immunoglobulin; RF, rheumatoid factor.
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11.8% for IgM with a specificity of 98.9%, 97.1%, and
93.9%, respectively (Table 3). The sensitivity for IgG and
IgA anti-CCP were highly significant in samples from pre-
RA patients compared with controls, whereas IgM anti-
CCP did not reach statistical significance (Table 3). The
sensitivity for all anti-CCP2 antibody isotypes were highly
significant in samples when patients were diagnosed with
RA compared with controls (Table 3).
The predictive value of various factors for developing
RA analysed in simple conditional logistic regression
was highest for the IgG anti-CCP2 test followed by IgA
anti-CCP. Smoking had a higher odds ratio for develop-
ing RA than HLA-SE, carriage of the PTPN22 1858T
variant and IgM anti-CCP (Table 4). In multiple condi-
tional regression analyses adjusted for HLA-SE, PTPN22
1858T variant and smoking, respectively, only the odds
ratio for IgM anti-CCP increased to 3.89, 95% CI 1.36
to 11.10, P < 0.05 when adjusted for the PTPN22 1858T
variant. In multiple conditional logistic regression ana-
lyses including IgG and IgA anti-CCP antibodies the
only isotype that remained significant was the IgG iso-
type, P < 5.9 × 10
-5 (data not shown).
The accumulated percentage of positive samples
(above cut-off according to ROC-curves) for each analy-
sis is presented in Figure 1a. The accumulated positivity
for IgG anti-CCP2 test was in almost complete concor-
dance with the previously analysed IgG anti-CCP2 test
using Euro-Diagnostica [1] while the positivity for both
IgA and IgM anti-CCP were lower (Figure 1a). Positivity
for IgA was apparent before that of IgM and was higher
during all time points preceding the onset of symptoms.
This pattern for the three isotypes was quite different
from that for RF isotypes where the first isotype to
appear was IgA followed by IgG and IgM; the two latter
were almost in complete concordance until less than
0.5 months before disease onset (Figure 1b). In pre-
patients the presence of anti-CCP antibodies, IgG and
IgA isotypes, was significantly associated with RA, irre-
s p e c t i v eo fp o s i t i v i t yf o rI g M ,I g Go rI g A - R F s( d a t an o t
shown). IgM-RF was independent of IgA anti-CCP anti-
body isotype associated with RA but not of IgG anti-
CCP isotype in pre-patients. In the RA patients both
anti-CCP antibodies (IgG and IgA isotypes) and IgM-RF
were independently associated with RA.
I nam u l t i p l el o g i s t i cr e g r e s s i o na n a l y s i si n c l u d i n g
IgM-RF and IgG anti-CCP isotype the relative risk for
development of RA was not significant for IgM-RF
alone, but the odds ratio for IgG anti-CCP isotype was
32.4 (9.0 to 116.9), P < 10
-6.T h eo d d sr a t i of u r t h e r
increased to 71.2 (9.9 to 566.7), P < 10
-4 by combination
of IgM-RF and IgG isotype suggesting an interaction of
IgM-RF with IgG anti-CCP antibody isotype in pre-
patients. In similar analysis of IgM-RF and IgA isotype
of anti-CCP antibodies the combination yielded a higher
odds ratio ((38.7 (4.6 to 321.6), P < 0.001) than for the
individual antibodies alone (odds ratio 3.8 (1.5 to 9.5),
P < 0.01 and 6.9 (2.6 to 18.4), P < 0.001, respectively).
Table 2 Concentrations (U/ml) (median values (IQR)) of
anti-CCP2 antibodies in pre-patients, matched controls
and RA patients
IgA-CCP2 IgG-CCP2 IgM-CCP2
Controls (n = 276)
a 0.8 1.2 18.5
(IQR) (0.5 to 1.1) (0.8 to 2.1) (11.1 to 34.3)
Pre-patients (n = 71)
b 1.1* 3.4 ** 21.6 *
(IQR) (0.6 to 2.1) (1.2 to 55.0) (10.1 to 55.3)
Patients (n = 53)
c 1.8*** 14.0 *** 51.9***
(IQR) (0.9 to 6.8) (11.4 to 715.5) (29.8 to 127.0)
p value
1 <0.001 <0.001 <0.001
a Analysis of IgM; n = 263 controls
b, Analysis of IgM; n = 68 pre-patient
samples,
cAnalysis of IgA; n = 54 and of IgG-CCP2; n = 59, * P < 0.05, ** P <
0.01, ***P < 0.001 pre-patients vs. controls or RA patients vs. controls,
1P-values
obtained from Kruskal-Wallis analysis comparing all three groups. Anti-CCP,
anti-cyclic citrullinated peptide; IQR, inter quartile range; Ig, immunoglobulin.
Table 3 Sensitivity and specificity for various anti-CCP2
antibody isotypes for 71 pre-patients, 274 matched
controls and 60 patients
Anti-CCP antibody Sensitivity Sensitivity Specificity
pre-patients patients
IgG
P 33.8*** 71.7*** 98.9
IgA
P 23.9*** 43.3*** 97.1
IgM
aP 11.8 32.8*** 93.9
IgG
E 32.4*** 71.2*** 98.5
The cut-off values for positivity for the antibodies were calculated using ROC
curves.
aAnalysis of IgM in pre-patients; n = 68, in patients; n = 58, and controls; n =
263,
E analysed with a kit from Euro-Diagnostica,
P analysed with a kit from
Phadia.***P < 0.001. Anti-CCP, anti-cyclic citrullinated peptide; ROC, receiver
operating characteristic; Ig, immunoglobulin.
Table 4 Simple conditional logistic regression analyses of
the different isotypes of anti-CCP2 antibodies, RFs, HLA-
SE, PTPN22 1858T and smoking in pre-patients and
matched controls
Factors OR (95%CI) P-value
IgG-CCP2 94.11 (12.74 to 695.41) <0.0001
IgA-CCP2 11.07 (4.36 to 28.09) <0.0001
IgM-CCP2 2.49 (0.98 to 6.29) 0.054
IgG RF 7.01 (2.82 to 17.42) <0.0001
IgA RF 15.87 (6.53 to 38.58) <0.0001
IgM RF 6.56 (2.77 to 15.50) <0.0001
HLA-SE 2.91 (1.47 to 5.76) 0.002
PTPN22 1858T 2.18 (1.15 to 4.12) 0.017
Smoking 3.12 (1.73 to 5.63) <0.0001
Only one sample from each individual has been included in the analyses.
Anti-CCP, anti-cyclic citrullinated peptide; HLA-SE, human-leukocyte antigen -
shared epitope; PTPN22, protein tyrosine phosphatase non-receptor type 22;
Ig, immunoglobulin.
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lysed in comparison for every separate individual
increased significantly over time and until the onset of
RA (P < 0.0001). The increase was already detectable in
samples from individuals collected up to five years
before onset of symptoms and thereafter the concentra-
tions remained fairly constant until 0.25 years before
onset of symptoms. Individuals sampled at the time
point of diagnosis compared with those 0.25 years
before onset of symptoms had significantly higher con-
centrations of IgG anti-CCP (P < 0.05; Figure 2). There
was also a significant gradual increase in the concentra-
tion of IgA anti-CCP until 0.25 years before onset of
symptoms (P < 0.05, including all time points before
Figure 1 Accumulated percentage positive samples of IgA, IgG and IgM isotypes. (a) Accumulated percentage positive samples of IgA, IgG
and IgM anti-CCP2 isotypes analysed using Phadia (P) and IgG anti-CCP2 using Euro-Diagnostics (E-D) in individuals before onset of symptoms
and at diagnosis of RA. (b) Accumulated percentage positive samples of IgA, IgG and IgM isotypes antibodies of rheumatoid factor in individuals
before onset of symptoms and at diagnosis of RA.
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including data at diagnosis (P <0 . 0 1 ) .T h e r ew a sn o
significant increase in concentrations of IgA anti-CCP
just before and when the disease was diagnosed in con-
trast to the increase in concentration of IgG anti-CCP
(Figure 2). There was also a significant increase in the
concentration of the IgM anti-CCP over time until 0.25
years before onset of symptoms (P <0 . 0 2 )a n da td i a g -
nosis (P < 0.001, including all time points) although it
was evident that the increase started later than for the
other isotypes; that is, actually three years or less before
onset of symptoms (Figure 2).
In pre-patients stratified for the absence or presence of
the different anti-CCP2 isotypes the pattern of signifi-
cantly increased cytokines was rather similar in IgA and
IgG anti-CCP2 antibody positive individuals with
increased concentrations of cytokines involved in general
immune activation such as IL-2 and IL-6, the Th1 related
cytokine IL-12, several Th2 related cytokines (IL-4, IL-9
and Eotaxin) and VEGF compared with antibody nega-
tives (Table 5). In IgA anti-CCP2-positive individuals
there was also significantly increased concentrations of
IL-1b and GM-CSF, whereas in IgG anti-CCP2 antibody
positive individuals the concentrations of IL-15, IFN-g
and IL-17 was significantly increased (Table 5). However,
after correction for multiple comparisons only IL-2Ra
and IL-2 in IgG isotype positive individuals remained sig-
nificantly increased P <0 . 0 5a n dP < 0.01, respectively).
There was a difference in the patterns of chemokines
r e l a t e dt ot h ed i f f e r e n ta n t i - C C Pi s o t y p e s ,w h e r et h e
only chemokine significantly increased in IgG anti-
CCP2-positive individuals was MIG, whereas in IgA posi-
tive individuals the concentrations of MCP-1, MIP-1b,
IP-10 and MIG were all significantly elevated compared
with IgA negative individuals (Table 5). MIG was the
only chemokine remaining significantly increased after
correction for multiple comparisons. There were no
significant differences in the concentrations of cytokines
and chemokines between IgM anti-CCP2 positive and
negative pre-RA patients (data not shown).
Pre-patient smokers had increased risk for developing
IgG anti-CCP (P = 0.04), while there was no relationship
between smoking and the other anti-CCP isotypes.
Although, in pre-RA patients who were smokers, IgA
anti-CCP antibodies appeared significantly earlier than
in non-smokers. The mean time was 2.4 years before
the onset of symptoms in smokers compared with
0.6 years in non-smokers. (P = 0.01). There was no dif-
ference for IgG and IgM anti-CCP in smokers versus
non-smokers. Also pre-RA patients who were smokers
were significantly more often IgA RF positive (P = 0.02).
There were no differences for the other RF isotypes
related to smoking habits (data not shown).
The predictive effect on radiological destruction at
disease onset and after 24 months of the different anti-
CCP2 isotypes in pre-patients was evaluated. The Larsen
score (mean ± SEM) at baseline (when diagnosed with
RA) was significantly higher in patients with IgG (6.6 ±
1.4) and IgM (9.2 ± 1.6) anti-CCP2 versus patients nega-
tive for the corresponding antibodies (3.4 ± 0.7 and
3.8 ± 0.7, respectively) for these isotypes before symp-
toms of joint disease (P < 0.05 for both isotypes).
Twenty-four months after diagnosis the Larsen score
was significantly higher in patients positive for IgG and
IgA anti-CCP (13.4 ± 2.4 and 13.6 ± 3.7, respectively)
but not for IgM before symptoms of disease compared
with those negative for the corresponding antibody.
There were also significant differences in Larsen score
at baseline between individuals positive for 0, 1, 2 or
more anti-CCP isotypes before the onset of symptoms
(mean score 2.9, 4.9 and 8.2, respectively, P < 0.05). The
same was observed for Larsen score after 24 months
(mean score 6.9, 8.5, and 17.8 respectively, P < 0.05).
Overall there was a significant increase in Larsen score
in all subgroups after 24 months compared with
baseline.
Individuals carrying HLA-SE alleles also had to a
greater extent IgG anti-CCP2 antibodies than those
lacking these alleles, although the difference was not sig-
nificant (P = 0.070). None of the other isotypes of anti-
CCP2 was associated with the carriage of HLA-SE
alleles. There was no relationship between any of the
anti-CCP2 antibodies and the PTPN22 1858T variant
(data not shown).
Discussion
In this study, we analysed the concentrations of the IgG,
IgA and IgM isotypes of anti-CCP2 antibodies and con-
structed ROC curves for the studied population.
Furthermore, we also related the presence of antibodies
of each isotype with previously analysed IgG, IgA and
1
10
100
1000
10000
IgA
IgG
IgM
Figure 2 Concentrations, in percentage of cut off value of anti-
CCP2 antibody isotypes before and at disease onset.
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kines collected at the same time points. In samples from
individuals before onset of joint symptoms, IgG and IgA
anti-CCP, with a higher frequency of individuals positive
for IgG anti-CCP, were the first antibodies to appear
before disease onset. IgM anti-CCP2 appeared later and
with a lower frequency. The anti-CCP isotype pattern
was quite different compared with RF. Sporadic cases
positive for all RF isotypes appeared much earlier in
time with the highest accumulated frequency of positive
individuals for IgA RF. IgG and IgM RF were very simi-
lar until less than 0.25 years before onset. Then just
Table 5 Concentrations of cytokines, cytokine related factors and chemokines (median, IQR, pg/mL) in pre-patients
stratified for the presence or absence of IgA and IgG isotypes of anti-CCP2 antibodies
IgA positive IgA negative P-value IgG positive IgG negative P-value
(n = 14) (n = 38) (n = 20) (n = 32)
Cytokine/chemokine
General activation
IL-1b 7.2 (2.9 to 36.4) 3.4 (2.3 to 5.1) 0.025 5.9 (2.3 to 25.5) 3.3 (2.3 to 4.9) 0.071
IL-1Ra 164.6 (128.7 to 454.9) 144.1 (96.5 to 195.5) 0.089 162.9 (109.7 to 408.6) 144.1 (99.8 to 186.5) 0.136
IL-2Ra 66.9 (38.6 to 110.0) 33.4 (22.3 to 51.3) 0.008 60.9 (35.9 to 88.7) 32.2 (20.8 to 47.6) <0.001
TNFa 108.1 (3.0 to 506.7) 49.1 (25.7 to 118.6) 0.556 85.4 (27.2 to 224.0) 45.0 (20.8 to 112.9) 0.234
IL-6 19.8 (5.9 to 147.7) 4.3 (1.1 to 11.5) 0.009 16.2 (3.6 to 111.6) 4.8 (1.1 to 8.2) 0.019
IL-2 74.7 (2.8 to 141.5) 3.8 (1.1 to 18.3) 0.020 49.1 (10.5 to 106.8) 1.4 (1.1 to 11.7) <0.001
IL-15 2.4 (0.2 to 9.6) 0.5 (0.2 to 4.2) 0.355 4.2 (0.8 to 4.2) 0.5 (0.2 to 4.2) 0.010
Th1 related
IL-12 54.4 (21.0 to 135.2) 21.2 (13.7 to 32.3) 0.033 53.5 (21.4 to 161.3) 20.5 (13.5 to 29.3) 0.012
IFN-g 113.4 (84.5 to 1711.0) 92.9 (50.5 to 150.1) 0.083 152.2 (97.1 to 1167.6) 78.5 (50.4 to 130.8) 0.022
Th2 related
IL-4 4.4 (3.2 to 26.4) 3.0 (2.2 to 4.2) 0.044 4.4 (3.3 to 17.4) 2.9 (2.3 to 4.0) 0.019
IL-5 5.6 (1.3 to 12.0) 5.8 (3.3 to 7.7) 0.675 5.8 (1.3 to 12.0) 5.8 (3.6 to 7.3) 0.441
IL-9 128.3 (22.7 to 283.6) 19.6 (5.7 to 85.9) 0.022 121.1 (24.7 to 255.9) 17.6 (5.6 to 71.7) 0.012
IL-13 5.1 (3.6 to 11.2) 4.4 (2.9 to 6.7) 0.329 5.3 (3.9 to 17.0) 4.0 (3.0 to 6.5) 0.089
Eotaxin 80.7 (43.2 to 429.8) 42.0 (26.1 to 53.1) 0.008 80.7 (44.0 to 363.8) 36.7 (26.0 to 47.6) 0.004
Th17 related
IL-17 31.3 (17.7 to 46.5) 22.3 (9.9 to 38.1) 0.082 31.5 (20.3 to 42.0) 21.2 (9.6 to 36.9) 0.040
Treg cell-related
IL-10 6.5 (3.8 to 19.8) 5.5 (3.6 to 8.1) 0.279 6.2 (3.2 to 18.4) 5.3 (3.9 to 7.6) 0.541
Bone marrow derived
IL-7 23.8 (19.2 to 36.8) 27.2 (18.6 to 37.4) 0.807 24.8 (13.4 to 42.1) 26.2 (20.8 to 36.6) 0.620
GM-CSF 23.0 (12.9 to 103.4) 5.0 (2.5 to 23.9) 0.008 20.2 (5.5 to 62.0) 4.6 (2.5 to 15.7) 0.054
G-CSF 57.1 (39.0 to 80.1) 58.7 (42.3 to 74.5) 0.463 57.1 (38.8 to 83.1) 58.7 (43.6 to 72.7) 0.527
Stromal cells and
angiogenic factors
bFGF 6.7 (2.2 to 14.1) 6.6 (2.2 to 6.8) 0.187 2.9 (1.6 to 11.2) 6.6 (3.5 to 6.8) 0.519
PDGF-BB 1905.9 (705.9 to
2387.4)
1985.6 (997.6 to
3160.0)
0.911 1975.9 (1109.6 to
3437.3)
1695.3 (950.6 to
2370.9)
0.312
VEGF 24.6 (10.0 to 63.7) 13.1 (5.7 to 23.9) 0.029 28.6 (12.0 to 53.1) 11.7 (4.9 to 15.0) 0.022
Chemokines
MIF 367.1 (90.8 to 538.2) 223.0 (142.1 to 461.5) 0.919 384.5 (163.2 to 599.4) 207.8 (123.7 to 366.5) 0.095
MIG 488.5 (319.0 to 1167.5) 272.9 (190.4 to 371.2) 0.004 425.6 (279.1 to 741.3) 272.9 (201.6 to 364.0) 0.039
IL-8 7.7 (3.6 to 11.4) 5.0 (0.5 to 10.2) 0.263 6.4 (0.5 to 12.1) 6.6 (1.7 to 9.4) 0.975
IP-10 962.1 (696.2 to 2214.2) 634.3 8425.0 to 1062.0) 0.014 957.0 (644.2 to 1855.8) 624.4 (420.0 to 1071.5) 0.061
MCP-1 23.0 (19.0 to 62.4) 18.5 (12.8 to 28.4) 0.028 25.8 (17.6 to 52.7) 17.3 (12.9 to 26.3) 0.085
MIP-1a 7.2 (4.2 to 11.7) 6.9 (4.8 to 10.0) 0.746 7.4 (2.9 to 11.9) 6.9 (5.1 to 9.3) 0.994
MIP-1b 44.2 (37.6 to 49.7) 35.7 (26.5 to 42.2) 0.030 42.9 (31.4 to 48.7) 36.5 (27.4 to 41.1) 0.200
IQR, inter quartile range; Ig, immunoglobulin; anti-CCP, anti-cyclic citrullinated peptide; IL, interleukin; TNF, tumor necrosis factor; IFN; interferon, GM-CSF,
granulocyte macrophage colony stimulating factor; G-CSF, granulocyte colony stimulating factor; bFGF, basic-fibroblast growth factor; PDGF, platelet derived
growth factor; VEGF, vascular endothelial growth factor; MIF, macrophage-migration inhibitory factor; MIG, monokine induced by interferon; MCP, monocyte
chemoattractant protein; MIP, macrophage inflammatory protein.
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markedly increased. To our knowledge, this is the first
study analyzing different isotypes of anti-CCP2 antibo-
dies before onset of symptoms of disease, thus there are
no comparable data. However, there are data published
on patients with established RA showing the same pat-
tern for anti-CCP2 isotypes with the highest frequency
of IgG (74.8%), followed by IgA (52.9%) and IgM
(44.5%) [9]. Also, it was shown that antibodies against
anti-viral citrullinated peptide of IgG and IgA isotypes
had a high specificity for discriminating RA [14]. In line
with Verpoort et al., the frequency of individuals posi-
tive for IgA anti-CCP2 was higher in RA than in undif-
ferentiated arthritis (UA) [8]. However, in our study of
individuals before onset of RA no limitations of included
subjects were performed compared with Verpoort et al.,
where only IgG anti-CCP positive subjects were
included [8]. In comparing the contribution from the
separate antibodies, we found that IgG and IgA were
associated with RA independent of IgM-RF both in pre-
patients and RA patients. IgM-RF was dependent of IgG
anti-CCP isotype in predicting RA in pre-patients but
not in RA patients. The analyses (both of IgG and of
IgA anti-CCP isotypes, respectively) and IgM-RF in
combination indicated an increase in odds ratio for
developing RA compared with having each antibody
separately, which is in line with the findings by Ioan-
Facsinay et al. [15].
In this paper the diagnostically most important anti-
CCP isotype was IgG, followed by IgA and IgM in pre-
patients. This order differed totally from our earlier
published RF isotype data, where IgA RF had the stron-
gest diagnostic impact, followed by IgM and then IgG
RF [1]. This inconsistency partly reflects the routine
clinical use of these antibodies where IgG anti-CCP and
IgM (and sometimes IgA) RF have the major diagnostic
strength; whereas IgG RF has a very low diagnostic sen-
sitivity. Hypothetically the IgM-dominated RF response
might represent a non-isotype switched T cell indepen-
dent immune response whereas the IgG-dominated CCP
pattern might reflect a mature T cell dependent immune
reaction. The pattern is, however, complex, as the IgM
anti-CCP increase appeared late, just a few years before
onset, in pre-patient samples, as could be expected in a
normal T dependent immune response, and as IgA RF,
representing a more mature isotype, appeared before
IgM RF.
As this study on ACPA in pre-RA samples concerns
the gradual increase from within the normal range to
highly positive levels and most ELISA based anti-CCP
assays focus on measurement of autoantibody levels
in the high (positive) range, we decided to instead apply
a fluorescence-based assay to be able to deliver
quantitative levels also in the normal range. By adjusting
this equipment that routinely measures IgG anti-CCP
we were able to measure also IgA and IgM anti-CCP
levels in pre-RA and control samples.
In our previous paper we found higher levels of cyto-
kines and chemokines in IgG anti-CCP positive patients,
[5] which was in line with the publication by Hueber et al.
[16]. Therefore, we undertook analyses of the cytokine and
chemokine concentrations stratified for the different anti-
CCP2 isotypes. In both IgA and IgG anti-CCP2 positive
individuals there was a similar pattern with increased
levels of proinflammatory cytokines (IL-2 and IL-6),
related factor (IL-2Ra), Th1 related cytokine (IL-12), Th2
related cytokines (IL-4, eotaxin and IL-9), and VEGF. On
the other hand, there was a striking difference in pre-RA
patients between individuals with IgA and IgG anti-CCP2
antibodies, where the levels of a number of chemokines
(IP-10, MCP-1 and MIP-1ß) were significantly increased
only in IgA anti-CCP positive individuals. The only che-
mokine remaining significant after correction for multiple
comparisons was MIG in IgA anti-CCP positives. We are
not sure how to interpret these results. In one study a
patient group were described to cluster together in micro-
array analysis having lower levels of IFN-g and TNF but
high expression of MCP-1 and MIP-1ß and was unlikely
to associate with anti-CCP2 antibodies (that is, of the IgG
isotype) compared with other groups related to anti-CCP2
antibodies [17]. These findings are interesting in the light
of our findings, that is, individuals with positivity for IgA
isotype who did not have increased concentrations of
TNF-and IFN-g b u to fM C P - 1a n dM I P - 1 ß .O ft h eI g A
anti-CCP positive individuals analysed for cytokines and
chemokines, 78.6% were also IgG positive in this study.
Given our limited cohort size it is difficult to separate the
effects of IgG and IgA anti-CCP, and these results should
optimally be repeated in a much larger pre-patient cohort.
In two studies it was shown that smokers had a higher
frequency of IgA [10,18] and IgM [18] anti-CCP2 antibo-
dies than patients who were non-smokers. In our study
there was an association between smoking and the devel-
opment of IgG anti-CCP2 antibodies and IgA RF pre-
diagnosis but not for the other autoantibody isotypes,
although the analysed subgroups were small. However, in
smokers IgA anti-CCP2 antibodies appeared with a sig-
nificantly longer predating time compared with non-
smokers positive for the IgA isotype. This could indicate
that smoking could be an environmental trigger for the
appearance not only of ACPA in general but especially
for the IgA isotype before onset of disease. The associa-
tion between smoking and IgA was not limited to anti-
CCP antibodies. Our finding that smokers were IgA
RF-positive significantly more often than non-smokers
among individuals before onset of symptoms of disease
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tion with a humoral autoimmunity switch to IgA produc-
tion. The subgroups in this study are, however, small,
and the results have to be interpreted with caution.
S t u d i e sh a v es h o w nt h a tt h ep r e s e n c eo fa n t i - C C P
antibodies is related to the radiographic progression in
RA [6,7] and the combination of IgA and IgG isotypes
have been suggested to identify a group of more severely
affected RA patients [10]. Recently a publication by van
der Woude et al. showed that in IgG anti-CCP2 anti-
body positive patients, the presence of more anti-CCP
antibody isotypes at baseline was associated with higher
radiographic score [11]. In our study we extend this by
showing that patients positive for more anti-CCP2 iso-
types already before onset of symptoms had a higher
radiographic score both at baseline and after 24 months
of disease compared with pre-RA individuals with fewer
or no anti-CCP2 isotypes before onset.
There are limitations to this study, such as the low
number of samples available, which makes it difficult to
stratify into subgroups. The effects of sample storage
time in small aliquots are also to be considered. This
was, however, compensated for by selecting controls
that were matched for the date of sampling and storage
conditions. The results of our analysis of IgG anti-CCP2
antibodies previously published [1] performed years
before the present IgG anti-CCP2 analysis was in almost
complete agreement with the present results, also
strongly arguing for the stability of the samples.
Conclusions
Anti-CCP2 antibodies of both the IgG and IgA isotypes
pre-dated the onset of RA by several years and also,
antibodies of both IgG and IgA isotypes predicted the
development of RA, with the highest predictive value for
IgG anti-CCP2 antibodies. There was a difference in the
pattern of up-regulated chemokines in IgA and IgG
anti-CCP positive individuals, and smoking brought for-
ward the appearance of IgA anti-CCP2 pre-RA; findings
that could indicate that these isotypes have different
functions in the pathogenesis of RA.
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